Medipharm Labs (Otc) ( (MEDIF) ) has released its Q2 earnings. Here is a breakdown of the information Medipharm Labs (Otc) presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
MediPharm Labs Corp., a pharmaceutical company specializing in precision-based cannabinoids, has reported a strong financial performance for the second quarter of 2025, marked by significant growth in its international medical cannabis segment. The company, known for its pharmaceutical-quality cannabis concentrates and derivatives, operates in both domestic and international medical markets.
In its latest earnings report, MediPharm Labs announced a 14% increase in revenue compared to the same period last year, reaching $11.8 million. This growth was largely driven by a 50% increase in international medical cannabis sales, which now account for 57% of the company’s total revenue. The company’s cash balance also improved significantly, rising to $10.4 million by the end of the quarter.
Key financial metrics from the report highlight a gross profit of $3.3 million, representing 28% of revenue, despite a decline due to product mix changes. Operating expenses, adjusted for a $2.2 million proxy contest expense, were reduced year-over-year. The adjusted EBITDA was reported at negative $0.6 million, showing an improvement in the year-to-date figures.
Looking ahead, MediPharm Labs remains focused on expanding its product portfolio and enhancing profitability. The management is optimistic about the company’s path to becoming EBITDA and cash flow positive, supported by its strong balance sheet and strategic cost management initiatives.